Positive Evidence Stacks Up For Takeda's Dengue Vaccine
Phase II Support For Durability, Dosing
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.
You may also be interested in...
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
CEO breaks down to Scrip how the Hong Kong-based company managed its way through the coronavirus outbreak in China, saying improvisation was critical.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.